UNSPSC 51334302: Clopenthixol

This classification denotes a dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A432D932A. European Medicines Agency schedules Clopenthixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06736MIG. Clopenthixol generally arises in the molecular formula C22H25CLN2OS.

The term CLOPENTHIXOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) CLOPENTHIXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clopenthixol under HS 29349990 and SITC 51579. As of Q4 2014, CLOPENTHIXOL remains the US FDA Preferred Term for this commodity. SMILES: C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)CL)CCO.

UNSPSC 51334302 Clopenthixol is a Commodity code that nominally covers a specific antipsychotic pharmaceutical, but recent state and local procurement activity under this code shows a significant mismatch: the only recent opportunity on record is Seminole County, Florida's IFB60459723LAS, which solicits Naloxone (an opioid antagonist) and Safe Drug Deactivation Systems — products entirely unrelated to clopenthixol's therapeutic class and clinical purpose. The county seeks 1,900 units of Naloxone and 800 deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building. This suggests either a tagging error in the state or local procurement system or a categorical misalignment in how the jurisdiction classified the opportunity. The scope of actual procurement activity under this code does not align with the pharmaceutical category it nominally represents.

Seminole County, Florida is the sole issuing body with recent activity recorded under this code. The IFB was posted on June 30, 2026, with a response deadline of July 26, 2023 — a date inconsistency in the source that suggests data quality issues in the underlying record. Vendors must submit bids electronically, comply with drug-free workplace certification and E-Verify requirements, maintain workers' compensation and commercial general liability insurance, and meet potential FEMA compliance obligations if the contract is federally funded. The contract terms include an initial two-year period with a one-year renewal option and a three-month probationary period allowing termination at the county's discretion. No explicit set-aside designations for disadvantaged enterprises are noted. Because this code shows minimal recent activity and that activity is unrelated to clopenthixol, the opportunity warrants caution; verify the correct UNSPSC classification before pursuing.